US › Healthcare

Nexalin Technology Inc. (NXL)

US · Healthcare · Medical Devices

$0.36-1.07%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$14,950
Revenue YoY
-63.5%
Net profit
$-2.1M
Profit YoY
-5.5%
EPS
$-0.11
EPS estimate
$-0.12
Net margin
-14,025.7%

EPS came in at -0.11 against a street estimate of -0.12 — a beat of 8.3%.

Key statistics

Market cap
$8.0M
Forward P/E
0.0
P/B
2.59
Book value
$0.14
EPS (TTM)
$-0.46
52-week high
$2.00
52-week low
$0.30
50-day MA
$0.43
200-day MA
$0.64
Beta
4.04

Analyst view

Analysts rate Nexalin Technology Inc. a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $2.00.

Shareholding

Insiders
10.50%
Institutions
4.89%

Largest institutional holders

FundStake
Geode Capital Management, LLC1.29%
Vanguard Group Inc0.93%
Vanguard Capital Management, LLC0.66%
Vanguard Fiduciary Trust Co0.27%
State Street Corp0.17%
Northern Trust Corp0.13%
HRT FINANCIAL LLC0.12%
Kovack Advisors Inc0.12%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nexalin Technology Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.